Beam Therapeutics (BEAM) Non Operating Income (2020 - 2026)

Beam Therapeutics (BEAM) has reported Non Operating Income for 7 consecutive years, with $12.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Income rose 17.72% year-over-year to $12.9 million; the TTM figure through Mar 2026 stood at $306.6 million (up 591.15% YoY), while the FY2025 annual figure was $303.7 million, up 681.43% from the prior year.
• Non Operating Income retreated to $12.9 million in Q1 2026 per BEAM's latest filing, from $261.7 million in the prior quarter.
• Across five years, Non Operating Income topped out at $261.7 million in Q4 2025 and bottomed at $2.5 million in Q1 2023.
• Historically, Non Operating Income has averaged $28.2 million across 5 years, with a median of $11.3 million in 2023.
• Annual changes were most pronounced in 2022 — Non Operating Income soared 4322.08% — and 2023, when it slumped 78.11%.
• Beam Therapeutics' Non Operating Income stood at $51.6 million in 2022, then plunged by 78.11% to $11.3 million in 2023, then slipped by 14.35% to $9.7 million in 2024, then jumped by 2603.11% to $261.7 million in 2025, then sank by 95.07% to $12.9 million in 2026.
• Business Quant data shows BEAM's Non Operating Income at $12.9 million in Q1 2026, $261.7 million in Q4 2025, and $14.1 million in Q3 2025.